Truist lowered the firm’s price target on Inspire Medical (INSP) to $235 from $250 and keeps a Buy rating on the shares. The company’s Q4 ...

Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $220 from $230 and keeps an Overweight rating on the shares. Though ...

RBC Capital Markets upheld a positive outlook on Inspire Medical Systems (NYSE:INSP) shares, reiterating an Outperform rating with a steady price target of $260.00. The stock currently trades at $180.

Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering ...

Chinese company says DeepSeek’s AI model will enhance data mining in its platform, delivering efficiency to hospitals and ...

President Biden's time in office has finally expired. But his signature legislative accomplishment—the Inflation Reduction ...

The improved performance came in the period premiums from medical insurance rose 22.8 percent to Sh46.3 billion.

If enacted in 2022, the Fair Pricing Act could have saved patients up to $213.4 million in out-of-pocket costs, research says.

Morgan Stanley (NYSE:MS) adjusted its outlook on Inspire Medical Systems (NYSE:INSP), reducing the price target from $230.00 to $220.00, yet continuing to endorse the stock with an Overweight rating.

President Donald Trump on Saturday signed executive orders imposing sweeping tariffs on the country’s three largest trading ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...